Targeting the ApoB100-ENO1 interaction with engineered peptides attenuates atherosclerotic inflammation and plaque progression
Translational Research · 2025
DOI: 10.1016/j.trsl.2025.12.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2025. Verfasst von Hyun Jung Yoo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea; Department of Internal…. Hauptthemen laut MEDLINE: Apolipoprotein B-100, Plaque, Atherosclerotic, Inflammation, Phosphopyruvate Hydratase. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea, National Research Foundation of Korea, Korean Society of Lipid and Atherosclerosis.
Abstract (Originalsprache)
BACKGROUND: Atherosclerosis, a chronic inflammatory disease, presents significant "residual risk" even with effective lipid-lowering therapies, primarily due to persistent vascular inflammation. Apolipoprotein B100 (ApoB100) acquires pro-inflammatory properties upon modification and binds to cell-surface enolase 1 (ENO1), an immune modulator upregulated in inflammatory conditions. This interaction induces inflammatory responses via NF-κB activation. Targeting the ApoB100-ENO1 interaction may offer a novel strategy to reduce vascular inflammation and atherosclerosis progression. METHODS: We developed PP3m, a stabilized ApoB100-derived peptide, to selectively inhibit the ApoB100-ENO1 interaction. Single-cell RNA sequencing (scRNA-seq) data from human atherosclerotic plaques were reanalyzed to characterize ENO1 expression in myeloid cells. In vitro, PP3m's anti-inflammatory effects were evaluated across various macrophage models stimulated by diverse inflammatory stimuli. Outcomes included cytokine secretion, inflammatory gene expression, foam cell formation, oxidized low-density lipoprotein (oxLDL) uptake, and signaling pathways activation. In vivo, Ldlr-/- mice fed an atherogenic diet were treated with PP3m to evaluate its effects on atherosclerosis progression, macrophage accumulation, and systemic inflammation. RESULTS: scRNA-seq analysis revealed that human atherosclerotic plaques harbor significantly more ENO1 macrophages, with ENO1 expression enriched in CD68+ M1 macrophages. Atherogenic stimuli induced ENO1 translocation to the plasma membrane in macrophages. In vitro, PP3m significantly attenuated inflammatory responses by suppressing IL-6 and CXCL8 secretion, reducing M1 polarization, and dose-dependently inhibiting oxLDL-induced foam cell formation and uptake. In vivo, PP3m reduced aortic lesion area, lipid content, and collagen deposition, accompanied by decreased macrophage accumulation in plaques and lower circulating pro-inflammatory cytokines. Importantly, these effects were independent of changes in plasma lipid profiles. CONCLUSIONS: The ApoB100-ENO1 axis is a critical driver of macrophage-mediated inflammation in atherosclerosis. The novel peptide PP3m effectively inhibits this interaction, reducing vascular inflammation and plaque progression without altering lipid levels. PP3m represents a promising therapeutic candidate for cardiovascular disease by targeting residual inflammatory risk through a lipid-independent mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea; Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080…
- Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan 31151, Republic of Korea; Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea; Research Institute for Convergence Science, Seoul National University, Seoul 08826, Republic…
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan 31151, Republic of Korea.
- Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan 31151, Republic of Korea; Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Republic of Korea. El…
Förderung
- Ministry of Science and ICT, South Korea
- National Research Foundation of Korea
- Korean Society of Lipid and Atherosclerosis
Zitieren
APA
Yoo, H. J., Vo, D. H. N., Kang, S. E., Lee, S. J., Soedono, S., Joo, E. J., Averia, M., Cho, K. W., & Song, Y. W. (2025). Targeting the ApoB100-ENO1 interaction with engineered peptides attenuates atherosclerotic inflammation and plaque progression. Translational Research. https://doi.org/10.1016/j.trsl.2025.12.003
Vancouver
Yoo HJ, Vo DHN, Kang SE, Lee SJ, Soedono S, Joo EJ, et al. Targeting the ApoB100-ENO1 interaction with engineered peptides attenuates atherosclerotic inflammation and plaque progression. Translational Research. 2025. doi:10.1016/j.trsl.2025.12.003
BibTeX
@article{Yoo2025,
author = {Yoo, Hyun Jung and Vo, Dan Hoang Nguyet and Kang, Shin Eui and Lee, Sang Jin and Soedono, Shindy and Joo, Esther Jin and Averia, Maria and Cho, Kae Won and Song, Yeong Wook},
title = {Targeting the ApoB100-ENO1 interaction with engineered peptides attenuates atherosclerotic inflammation and plaque progression},
journal = {Translational Research},
year = {2025},
doi = {10.1016/j.trsl.2025.12.003}
}
EUVIMED